Michael Barbella, Managing Editor01.26.23
Soundbite Medical Solutions Inc. (SBMS) has reached an exclusive product licensing agreement with VFLO Medical (VFLO).
“The growing prevalence of atherosclerotic vascular disease burdened by calcium has become a serious public health problem in China. We are excited to partner with the Soundbite team and look forward to bringing the unique technology and portfolio of treatment solutions to patients in Greater China that suffer from calcified arterial disease,” VFLO President/CEO Dong Wu said.
Soundbite has granted VFLO an exclusive license for certain proprietary products including its SoundBite Crossing System and the Active Microcatheter System. Under the agreement, VFLO will manufacture, develop, and commercialize the products in the greater China region, including mainland China, Hong Kong, Macau, and Taiwan. In return, Soundbite will receive an upfront fee, subsequent milestone payments, plus royalties from sales of such products. The terms also allow cross-licensing on future improvements of the products, aligning both companies focus on innovation.
“We are thrilled to work with VFLO to bring our revolutionary shock wave technology to patients in China, opening a key market for our company with experienced partners in VFLO. Bringing non-dilutive capital to our shareholders provides us with the opportunity to build meaningful value while serving patients in the growing Chinese market,” Soundbite Medical President/CEO Lori Chmura said.
Soundbite is a privately-held medical device company that develops solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to treat patients suffering from calcified and occlusive cardiovascular disease.
“The growing prevalence of atherosclerotic vascular disease burdened by calcium has become a serious public health problem in China. We are excited to partner with the Soundbite team and look forward to bringing the unique technology and portfolio of treatment solutions to patients in Greater China that suffer from calcified arterial disease,” VFLO President/CEO Dong Wu said.
Soundbite has granted VFLO an exclusive license for certain proprietary products including its SoundBite Crossing System and the Active Microcatheter System. Under the agreement, VFLO will manufacture, develop, and commercialize the products in the greater China region, including mainland China, Hong Kong, Macau, and Taiwan. In return, Soundbite will receive an upfront fee, subsequent milestone payments, plus royalties from sales of such products. The terms also allow cross-licensing on future improvements of the products, aligning both companies focus on innovation.
“We are thrilled to work with VFLO to bring our revolutionary shock wave technology to patients in China, opening a key market for our company with experienced partners in VFLO. Bringing non-dilutive capital to our shareholders provides us with the opportunity to build meaningful value while serving patients in the growing Chinese market,” Soundbite Medical President/CEO Lori Chmura said.
Soundbite is a privately-held medical device company that develops solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to treat patients suffering from calcified and occlusive cardiovascular disease.